Leon Recanati
Known title: DirectorCIK: 0000919590
Leon Recanati's purchase track record
Leon Recanati has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/4/2026 | EVGN | $692K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| EVGN | ▲ Buy | Open Market | 460,000 | $292K | 8/11/2026 | View on chart |
| EVGN | ▲ Buy | Open Market | 800,000 | $400K | 8/4/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Evogene gets 180-day extension for Nasdaq bid price compliance
Evogene announced that Nasdaq granted an additional 180-day period to regain compliance with the minimum bid price requirement. This extension allows the company until March 29, 2027, to meet the exchange's listing standards. The news highlights ongoing challenges for the stock, which has traded as low as $0.35 over the past year.
Evogene gets 180-day extension for Nasdaq bid price compliance. Evogene announced that Nasdaq granted an additional 180-day period to regain compliance with the minimum bid price requirement. This extension allows the company until March 29, 2027, to meet the exchange's listing standards. The news highlights ongoing challenges for the stock, which has traded as low as $0.35 over the past year.